The ongoing debate regarding the use of [2 agonists in asthma, together with the recent availability of long acting drugs such as eformoterol and salmeterol, has resulted in a critical reappraisal of their role as first line bronchodilator therapy.' In particular, it has been postulated that prolonged receptor occupancy with long acting 2 agonists might conceivably result in the development of tolerance. In this respect it has recently been shown with salmeterol that tolerance occurs to its protective effects against methacholine and exercise induced bronchoconstriction. 23 We have also previously demonstrated that significant bronchodilator subsensitivity develops after four weeks of continuous therapy with inhaled eformoterol (Ciba-Geigy, Basle, Switzerland) in a dose of 24 ptg twice daily given as a metered dose aerosol to patients with asthma.4 However, it was felt that this preliminary study4 might be open to criticism because of small patient numbers and a non-significant trend towards a higher baseline for forced expiratory volume in one second (FEV,) 12 hours after treatment with eformoterol compared with placebo. It was therefore possible that this carryover effect on baseline FEV, with eformoterol could have a confounding effect on the subsequent bronchodilator dose-response curve. A dry powder delivery system for eformoterol has since become available and it was felt necessary to assess whether tolerance occurs with this new formulation.
The aim of the present study was to compare airways and systemic P2 adrenoceptor responses after continuous therapy with inhaled eformoterol given as a dry powder or placebo to patients with stable, reversible, mild to moderate asthma. As in the previous study using the metered dose aerosol, an identical dose of eformoterol (24 ig twice daily) with the same duration of treatment (four weeks) was used. However, in order to obviate possible confounding effects of baseline on the doseresponse curve, the latter was performed 24 hours after the previous dose rather than 12 hours as in the previous study. Subjects attended the laboratory at the third and fourth visits at the same time between 08.00 and 09.00 hours, after eformoterol and placebo, having withheld their study medication for 24 hours, their rescue medication for at least 12 hours, and oral theophylline for 48 hours. An intravenous cannula was inserted and kept patent with bolus injections of heparinised saline. Cannula dead space of 2 ml was withdrawn before blood samples were collected. After a 30 minute period of supine rest, 30 ml of blood was collected for the determination of the parameters of lymphocyte P2 adrenoceptor function. It was required that baseline FEVy (prior to the dose-response curve) must not differ from the value at the randomisation visit by more than 15%; this did not occur in any of the 16 completed patients. The dose-response curve was then constructed with inhaled eformoterol using doses of 6 jig, 24 jig, 24 jig and 48 jig -that is, a cumulative dose of 102,g after the last dose -via the inhaler device, with the doses being separated by 50 minutes. Measurements of FEVy, FEF2575, serum potassium (K), heart rate (HR), systolic and diastolic blood pressure (SBP, DBP), postural finger tremor (Tr) and ECG parameters (T-wave, Q-Tc) were undertaken over a 20 minute period at baseline (after the rest period), 30 minutes after each dose, and repeated at 1, 2, 4, and 6 hours after the final dose. In addition, at one hour after the last dose of the dose-response curve the patient's subjective grading oftremor and heart beat were measured using an analogue chromatic continuous scale from 0 (no sensation) to 100 mm (unbearable). Serum potassium was measured by flame photometry (IL943 Analyser, Instrumentation Laboratory Ltd, Warrington, UK) with analysis being performed in batches at the end of the study and samples being assayed in duplicate. The coefficients of variation for analytical imprecision within and between assays were 0-42% and 0 47%, respectively. The normal reference range for our laboratory is 3 5-5 5 mmol/l.
The electrocardiogram was recorded on a standard lead II using a Hewlett-Packard (Palo Alto, California, USA) monitor and printer with paper speed set at 50 mm/s and 0 5 mV/ cm again. The following parameters were measured from the mean of five consecutive complexes: R-R interval (s), Q-T interval (ms) and T wave (mV). The Q-T interval was measured using the method described by Shamroth7 to account for the presence of U waves. The formula of Bazett8 was used to correct the Q-T interval for heart rate (Q-Tc). The heart rate was calculated from the R-R interval. Systolic and diastolic blood pressures were recorded by a semi-automatic sphygmomanometer (Dinamap Vital Signs Monitor, Critikon, Tampa, USA). All measurements were taken from the right arm at one minute intervals until recordings were constant. The mean of three consistent readings was used for the purpose of analysis.
Finger tremor was recorded by a previously validated method9 using an accelerometer transducer (Entran Ltd, Ealing, UK). Five recordings were measured and results stored on computer disc for subsequent spectral analysis of total tremor power >2 Hz (units of mg'/s) using computer-assisted autocovariance. The mean of three consistent readings was subsequently analysed. Power calculations were based on a sample size of 12 patients in order to detect a 03 1 difference in delta FEV, response -that is, change from baseline from dose-response curve -and a 0 3 mmol/l difference in delta potassium response with a [ error of 0-2 (80% power) and ac error set at 0`05 (two tailed). In order to increase the power ofthe study to 90% a total of 16 patients were recruited to completion.
Since power calculations were based on change from baseline, all variables were analysed as delta responses, with data for finger tremor and Bmax having been transformed using logarithm to base 10 as both variables were not normally distributed. Data were analysed using a Statgraphics statistical software package (STSC Software Publishing Group, Rockville, USA). For all parameters comparisons between treatments were made by multifactorial analysis of variance using subjects, treatments, and period effects as within factors for the analysis. A p value of <0 05 (two tailed) was considered as being of significance. Values are shown in the text as means for each treatment and 95% confidence intervals for the differences between treatments. Since the response-time profile only provides a group mean response at a given time point, it is conceivable that peak effects may have occurred at different time points for each subject. Thus, FEV, and FEF2,575 responses for each individual were also analysed to ascertain the true peak response rather than the apparent peak from the response-time profile. For the lymphocyte 12 adrenoceptor binding parameters -that is, Bmax and Kd -a technical problem with the cell harvester resulted in evaluable data being 
Discussion
The results of the present study showed that, compared with placebo, there was significant blunting of the peak delta FEV, response to eformoterol from the dose-response curve after continuous treatment for four weeks with inhaled eformoterol given twice daily as a dry powder. Furthermore, there was evidence to suggest that subsensitivity also developed to the duration of the bronchodilator effect of eformoterol six hours after the last dose of the dose-response curve. Indeed, this was observed for both delta FEV, and delta FEF2575, sug- gesting that subsensitivity may have developed in both large and small airways.
It is important to point out that the magnitude of difference in delta FEV1 at six hours after the last dose (035 1) was twice that of peak delta FEV, (0-16 1), suggesting that tolerance to the duration of response may be the more relevant finding. These data are in agreement with results from our previous study with metered dose aerosol4 which also showed that the magnitude of difference in the bronchodilator response between eformoterol and placebo was largest after six hours. However, in the present study baseline values for FEV, and FEF25 15 were not significantly different, and hence this is unlikely to have been a confounding factor on the subsequent doseresponse curve. It is therefore likely that the observed bronchodilator subsensitivity was a real effect.
The clinical relevance of these findings is difficult to assess. However, since eformoterol is fast acting it is conceivable that patients might use it repeatedly for rescue relief of bronchoconstriction, as might occur during an acute attack. It would therefore be interesting to know how continuous exposure to eformoterol affects the acute bronchodilator response to repeated puffs of inhaled salbutamol. Since salbutamol is a weaker 02 agonist than eformoterol, it is probable that subsensitivity would be more likely to be uncovered under conditions of submaximal receptor stimulation as might occur if salbutamol was used to construct the dose-response curve. Since peak flow data were only available for the last week of each treatment, we cannot say whether the effects of eformoterol 24 pg twice daily were maintained or attenuated during the four week treatment period. However, it was evident that morning and evening peak flows were much higher during eformoterol than with placebo at the end of the four week treatment period, suggesting that its effects were probably maintained.
We have therefore now described the development of subsensitivity to the bronchodilator effects with both aerosol and dry powder formulations of inhaled eformoterol in asthmatic patients. There is evidence to suggest that tolerance does develop to the protective action of inhaled long acting 12 agonists against bronchoconstrictor stimuli such as methacholine and exercise.23 However, previous studies which have attempted to evaluate subsensitivity to the bronchodilator effects of both eformoterol and salmeterol have been difficult to interpret as a consequence of inadequate run-in and washout periods without 12 agonists"-13 or the absence of dose-response curves." 14 It should be emphasised that in vitro data using precontracted guinea pig trachea or human bronchus have demonstrated eformoterol to be a full agonist, with greater intrinsic activity than salmeterol which acts as a partial agonist at the 12 adrenoceptor.5 1`8 However, it remains unclear whether such differences in intrinsic activity will be relevant in terms of a greater propensity for inducing 12 adrenoceptor downregulation with eformoterol compared with salmeterol.
It is interesting to note that two previous placebo controlled chronic dosing studies using short acting P2 agonists'920 have demonstrated a maintained peak bronchodilator effect, but in the non-placebo controlled study by It should be mentioned that, although bronchodilator subsensitivity was demonstrated to inhaled eformoterol, a clinically significant improvement in delta FEV, both at peak (0 841) and at six hours after the last dose (0 581) was observed after regular therapy with eformoterol when compared with the initial baseline value. Furthermore, as in our previous study,4 morning and evening peak flow values were significantly higher and rescue requirements significantly lower after treatment with eformoterol compared with placebo. The improved peak flow values might conceivably lead to a delay in patients seeking medical attention during an acute exacerbation, and possibly result in a perceived false sense of security. However, it should be emphasised that it may not be possible to extrapolate these findings to patients with severe asthma in terms of producing a reduced response to nebulised salbutamol during an acute attack. It is also worth noting that most of our patients were receiving inhaled corticosteroid which did not prevent the development of bronchodilator subsensitivity.
The subsensitivity of the bronchodilator response was mirrored by blunting of lymphocyte P2 receptor binding density. It responses our results showed that effects were beginning to wear off by six hours after the last dose of the dose-response curve. This suggests that there may be differences in duration of action between airway and systemic 12 adrenoceptors, which may be a reflection of the respective differences in local drug concentration.
In summary, we have shown significant bronchodilator subsensitivity after continuous therapy with eformoterol given twice daily as a dry powder formulation, which is in keeping with our previous study using an aerosol formulation. Similar changes were also observed in terms of lymphocyte P2 adrenoceptor downregulation and tolerance of systemic P2 responses. Placebo controlled studies are now required to further evaluate bronchodilator responsiveness with other long acting P2 agonists such as salmeterol, after regular treatment.
